Topical Medications as First-Line Treatment Options for Orofacial Pain
Drug Topics
FEBRUARY 24, 2025
Researchers investigated the pharmacological management of chronic orofacial pain and provided guidance on its proper treatment.
Mon.Feb 24, 2025
281 
Kennedy’s MAHA agenda is tackling ‘conflicts of interest’ — and could take aim at FDA adcomms
PharmaVoice
FEBRUARY 24, 2025
Health agency job cuts and a newly-established MAHA commission leave many unanswered questions about potential reforms and impact on drug approvals.
Join 5,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Two New Stelara Biosimilars Now Available in US
Drug Topics
FEBRUARY 24, 2025
Yesintek from Biocon Biologics and Pyzchiva from Sandoz will have a patient assistance program that includes benefits verification and copay support.
What happens if you miss a dose of blood thinner?
The Checkup by Singlecare
FEBRUARY 24, 2025
Blood thinners are prescription drugs that keep your blood from thickening or clumping, preventing potentially life-threatening blood clots. They include anticoagulant and antiplatelet medications like heparins , Coumadin ( warfarin ), and aspirin , as well as newer-generation anticoagulants like Eliquis (apixaban) and Xarelto (rivaroxaban). Although they dont actually make your blood thinner, these medications reduce your bodys normal blood clotting response to prevent existing blood clots from
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
FDA Grants Emergency Authorization to Aptitude’s COVID, Flu Test
Drug Topics
FEBRUARY 24, 2025
The next-gen molecular Metrix was given emergency use authorization for its ability to test for SARS-CoV-2 and influenza A and B viruses.
Lifileucel Approval Paves the Way for Personalized Minimally-Invasive T-Cell Therapies
Pharmacy Times
FEBRUARY 24, 2025
The FDAs accelerated approval of lifileucel (Amtagvi; Iovance Biotherapeutics) marks a major milestone in immunotherapy for metastatic melanoma, building on decades of research in tumor-infiltrating lymphocyte therapy.
Signup to get articles personalized to your interests!
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
More Trending
Fierce Healthcare - Untitled Article
Fierce Healthcare
FEBRUARY 24, 2025
Elon Musk is facing a lawsuit from federal workers over a mass email requiring government employees to list productive tasks from the prior week or risk termination. HHS leadership has instructed its staff not to respond to the message, at least temporarily.
FDA Approves Updated Buprenorphine Label For Rapid Initiation Treatment
Drug Topics
FEBRUARY 24, 2025
The updated label also includes alternative injection sites, such as the abdomen, thigh, buttock, or back of the upper arm.
Fierce Healthcare - Untitled Article
Fierce Healthcare
FEBRUARY 24, 2025
Federated imaging network startup Avandra has raised $17.5 million in series A funding togive researchers access to larger volumes of imaging data to train AI models or develop novel therapie | The series A round was co-led by Aegis Ventures and SpringRock Ventures. An executive from each company will join the board of Avandra.
Semaglutide shortage ends as FDA sets deadline for compounders
Pharmaceutical Technology
FEBRUARY 24, 2025
With Novo Nordisks blockbuster drugs Wegovy and Ozempic back in stock, copycat versions are no longer allowed for now.
Position Your Pharmacy for Expansion
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Fierce Healthcare - Untitled Article
Fierce Healthcare
FEBRUARY 24, 2025
A Friday order granted higher education plaintiffs' request to block in part the termination of funding for "equity-related" grants or contracts, and partially slowed a directive to potentially bring enforcement actions against private entities with diversity, equity and inclusion practices.
Transforming manufacturing and packaging at PHARMAP 2025
Pharmaceutical Technology
FEBRUARY 24, 2025
PHARMAP 2025 takes place on 14-15 April 2025 in Berlin, Germany.
From Tumor Biology to Breakthrough Therapies: The Rise of Personalized Cancer Vaccines
Pharmacy Times
FEBRUARY 24, 2025
Advancements in neoantigen vaccines and immunotherapy are transforming cancer treatment by leveraging genomic sequencing to overcome tumor heterogeneity and therapeutic resistance.
Fierce Healthcare - Untitled Article
Fierce Healthcare
FEBRUARY 24, 2025
Hims & Hers' business is booming and the company projected 2025 revenue to hit $2.3 billion. But shares of the company dropped 19% in after-hours trading as skittish investors are still concerned about shifts in the GLP-1 market.
What the FDA's New Dosage Guidance Means for the Future of Clinical Research
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
James P. Allison and the Discovery of CTLA-4: How Immune Checkpoint Blockade Revolutionized Oncology
Pharmacy Times
FEBRUARY 24, 2025
Immunotherapy pioneer James P. Allison, PhD, revolutionized cancer treatment by discovering immune checkpoint blockade, leading to significant advances in survival rates and ongoing efforts to optimize immuno-oncology strategies.
FDA clears first therapy for rare disease CTX from Mirum
pharmaphorum
FEBRUARY 24, 2025
Mirum Pharma's Ctexli has become the first FDA-approved therapy for ultra-rare disease cerebrotendinous xanthomatosis (CTX)
Omalizumab Shows Superiority Over Immunotherapy in Stage 2 of OUtMATCH Study
Pharmacy Times
FEBRUARY 24, 2025
The FDA-approved treatment did not cause as many adverse events as immunotherapy when treating patients with multi-food allergy.
Fierce Healthcare - Untitled Article
Fierce Healthcare
FEBRUARY 24, 2025
Marketing for Medicare Advantage plans paints seniors with a broad brush. These lifestyle ads show the seniors we want to beactive, independent and vibrant. | The entire U.S. healthcare system, including health plans, must adapt to meet the needs of the rapidly aging population.
5 Reasons to Upgrade Your Pharmacy Management Software
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Troubled gene therapy player bluebird sold for a song
pharmaphorum
FEBRUARY 24, 2025
At risk of defaulting on financial commitments, gene therapy firm bluebird bio has agreed to sell itself to private equity firms at a knockdown price.
Tanshinlactone May Inhibit the Growth of ER+, HER2+, or EGFR-Mutated Cells in Breast Cancer
Pharmacy Times
FEBRUARY 24, 2025
Tanshinlactone is an active ingredient that is commonly used in Chinese herbal medicine.
FDA looks at Opdivo/Yervoy in first-line colorectal cancer
pharmaphorum
FEBRUARY 24, 2025
The FDA has started a priority review of Bristol Myers Squibb's Opdivo and Yervoy as first-line therapy for MSI-H and dMMR colorectal cancer
Key Considerations for Pharmacists in Hemophilia B Treatment With Etranacogene Dezaparvovec
Pharmacy Times
FEBRUARY 24, 2025
Etranacogene dezaparvovec offers a long-term, cost-effective solution for hemophilia B by providing sustained factor IX expression but requires careful patient selection and post-infusion liver monitoring.
“Digital genocide”: BMJ post alleges patient data deletion amid DEI purge
Pharmaceutical Technology
FEBRUARY 24, 2025
In an anonymous post in the BMJ, the author claims that words relating to DEI could lead to grants being taken away.
B-Together Trial Demonstrates Efficacy of Bepirovirsen Followed By Peg-IFN for HBV
Pharmacy Times
FEBRUARY 24, 2025
The long-term durability of response will be evaluated in the B-Sure trial (NCT04954859), which will enroll patients with hepatitis B virus (HBV) from B-Together (NCT04676724).
MeiraGTx seeks UK approval after gene therapy restores sight in children born blind
Pharmaceutical Technology
FEBRUARY 24, 2025
MeiraGTxs investigational gene therapy AAV-AIPL1 has improved the sight of 11 children who were born blind.
Molecular COVID/Flu Multiplex Test is Granted FDA Emergency Use Authorization
Pharmacy Times
FEBRUARY 24, 2025
The test results are available in as little as 20 minutes.
Fierce Healthcare - Untitled Article
Fierce Healthcare
FEBRUARY 24, 2025
Clinical laboratory and pathology diagnostics have been at the center of technological innovation in healthcare since the inception of the light microscope. Today, that continues with AI, digital pathology, and mass spectrometry. These rapidly progressing technologies are helping spur the transformation of diagnostic medicine.
Compounders cast adrift after semaglutide shortage ends
pharmaphorum
FEBRUARY 24, 2025
The FDA has said there is no longer a shortage in the US market for Novo Nordisk's GLP-1 agonist semaglutide, ending sales of compounded forms.
Evaluating Options for Respiratory Syncytial Virus Prophylaxis
Pharmacy Times
FEBRUARY 24, 2025
Curbing RSV and its complications can reduce health care costs associated with its treatment.
EC authorises Celltrion’s Avtozma for multiple indications
Pharmaceutical Technology
FEBRUARY 24, 2025
Celltrion has secured marketing authorisation from the EC for Avtozma, a biosimilar to Chugai Pharmaceuticals RoActemra (tocilizumab).
Expert: Overcoming Barriers to Wider Biosimilar Adoption
Pharmacy Times
FEBRUARY 24, 2025
Gaps in education about biosimilars, particularly among pharmacists, patients, and prescribers, are a significant barrier to wider adoption.
Pharma Pulse 2/24/25: Picking Markets for a Global Launch Strategy, Semaglutide Holds Promise in Reducing Alcohol Cravings & more
Pharmaceutical Commerce
FEBRUARY 24, 2025
The latest news for pharma industry insiders.
Patient Counseling and Management of Adverse Events
Pharmacy Times
FEBRUARY 24, 2025
Panelists discuss how pharmacists serve as essential medication experts by providing comprehensive counseling on VMAT2 inhibitors, including proper administration, expectations for symptom improvement, potential side effects, and drug interactions, while playing a vital role in monitoring older adult patients through regular check-ins, medication therapy management services, and collaboration with the healthcare team to optimize treatment outcomes.
Let's personalize your content